Every claim, every source.

This 2025 systematic review specifically addresses how intermittent fasting affects fertility and reproductive hormones in women with polycystic ovary syndrome (PCOS) — the most common endocrine disorder of reproductive-aged women, characterized by hyperandrogenism, insulin resistance, and menstrual irregularity. The authors synthesized three included studies of time-restricted feeding (TRF) and related IF protocols in PCOS patients. The findings were notably favorable. Menstrual regularity improved in 33–40 percent of participants — meaning a third or more of women with previously irregular cycles reported normalized cycling after TRF intervention. Hormonal changes pointed in the right direction for the PCOS phenotype: total testosterone fell about 9 percent, free androgen index dropped 26 percent, sex hormone-binding globulin rose, and anti-Müllerian hormone and luteinizing hormone both decreased. The review concludes that intermittent fasting, particularly time-restricted feeding, shows potential as a non-pharmacological adjunct intervention for improving reproductive health and fertility in women with PCOS by addressing the core pathophysiological mechanisms (insulin resistance, hyperandrogenism) that drive the syndrome.

This 2024 Nature Cell Biology paper from the Madeo lab identified spermidine — a polyamine found in many foods (wheat germ, soybeans, mushrooms, aged cheeses) and produced endogenously — as the essential mediator of fasting-induced autophagy. The authors ran experiments across multiple model systems: yeast, nematodes, mouse cells, and human cell lines (U2OS osteosarcoma cells and H4 neuroglioma cells). Across all systems, blocking spermidine synthesis with the inhibitor DFMO suppressed fasting-induced autophagy — and supplementing exogenous spermidine (100 µM) rescued the autophagy response. The paper also reports human-cohort metabolomics: across multiple cohorts of fasting participants (61 to 109 volunteers per cohort, fasting durations 3 to 16 days), serum spermidine levels rose during fasting. Human PBMCs showed increased hypusination of eIF5A — a downstream effect linking spermidine to translation control and autophagy machinery. The paper's mechanistic claim is significant: spermidine is not just correlated with fasting-induced autophagy; it is required for the response to occur.

This review compares the cardiovascular benefits of eating whole sardines against taking isolated fish-oil supplements. The authors argue that whole sardines provide a "matrix" of nutrients that fish-oil capsules lack: not just EPA and DHA, but calcium, vitamin D, B12, selenium, high-quality protein, and minor compounds (taurine, coenzyme Q10) absent from purified oils. Per 100 grams of cooked sardines, the USDA database reports 24.6 g of protein, 11.5 g of total fat, 473 mg of EPA, 509 mg of DHA, 382 mg of calcium, 4.8 µg of vitamin D, 8.9 µg of B12, and 52.7 µg of selenium. The review surveys randomized trials of sardine consumption versus control diets and concludes that whole-sardine intake produces favourable changes in lipid profile, inflammation markers, and insulin sensitivity, with the additional minerals and protein doing work that omega-3 supplements alone cannot. The framing throughout is that sardines outperform fish-oil supplementation as a delivery vehicle for cardiovascular benefit.

Narrative review consolidating the evidence base for relative energy deficiency in male athletes — the male-specific extension of the original female RED-S framework. The authors synthesize controlled trials and observational cohorts showing that male endurance athletes operating below approximately 30 kcal/kg fat-free mass per day for as little as five days exhibit measurable HPG-axis disruption: LH pulsatility falls, total testosterone falls, T3 falls, and bone-formation markers fall. In elite male endurance runner cohorts, total testosterone runs 55–85% of age-matched sedentary norms, roughly 40% of one cohort showed clinically low testosterone, and bone stress injury risk runs approximately 4.5× control. The paper extends the Loucks 2003 30 kcal/kg/day energy availability threshold from women to lean male athletes.

The FDA and EPA jointly publish dietary fish-consumption guidance for the U.S. public, including specific advisory recommendations for pregnant women, breastfeeding women, women of childbearing age, and young children. Fish species are categorized into "Best Choices" (eat 2–3 servings per week), "Good Choices" (eat 1 serving per week), and "Choices to Avoid" (do not eat — high methylmercury). Sardines appear in the "Best Choices" category alongside anchovies, salmon, herring, and other small-pelagic species. The advisory provides the species-by-species mercury-content basis for these recommendations and includes guidance on portion sizing for adults and children. The 2022 update reflects ongoing review of mercury data, omega-3 dietary modeling, and population-health evidence on fish consumption patterns.

This Nutrients review is the first to synthesize specifically what human trials of intermittent fasting (not animal work, not religious fasting) show about sex-hormone shifts in women and men. The authors identified seven human trials total: five testing time-restricted eating, one testing a 5:2 protocol, and one studying meal timing. Their headline findings for premenopausal women with obesity: intermittent fasting reduces testosterone and the free androgen index, and increases sex hormone-binding globulin — particularly when the eating window is restricted to earlier in the day. Estrogen, luteinizing hormone, and follicle-stimulating hormone showed no statistically meaningful change in the trials reviewed. In men, intermittent fasting reduced total and free testosterone in some studies, with implications for libido and lean-mass maintenance that the authors flag as concerning at longer protocol durations. The honest summary: female reproductive hormone effects are real but modest, mostly favorable for PCOS-spectrum profiles, and depend heavily on eating-window timing.

This study used data from the Canadian Study of Adolescent Health Behaviors — a national survey of 2,762 adolescents and young adults — to ask how common intermittent fasting is and whether it correlates with eating-disorder behaviors. The engagement numbers were striking: roughly 48 percent of women, 38 percent of men, and 52 percent of transgender or gender-non-conforming respondents reported practicing some form of intermittent fasting in the past 12 months. The researchers used the Eating Disorder Examination Questionnaire alongside modified Poisson regression to measure associations. Across all three gender groups, intermittent fasting in the past 12 months and the past 30 days was significantly associated with elevated eating-disorder psychopathology — disordered cognitions, restrictive behaviors, and binge-purge cycles. The pattern was strongest and most consistent in women. The authors do not claim fasting causes eating disorders; the data are cross-sectional and cannot prove direction. They argue clinicians screening young patients should treat self-reported intermittent fasting as a meaningful flag.

This randomized controlled trial enrolled 71 adults with metabolic syndrome and randomized them to a five-day modified Buchinger-style fast followed by a modified DASH diet versus DASH diet alone. Investigators measured 16S rRNA gut microbiome composition, ambulatory blood pressure, antihypertensive medication requirements, and standard cardiometabolic biomarkers at baseline, immediately post-fast, and at three months follow-up. The fasting plus DASH arm showed greater reductions in systolic blood pressure, in the requirement for antihypertensive medications, and in body-mass index at three months than the DASH-only arm. Gut microbiome analysis identified specific bacterial taxa — including changes in genera linked to short-chain fatty acid production and to microbial pathways relevant to host metabolic regulation — that responded to the fast, with changes that partly persisted into the post-fast period. The paper is one of the few human RCTs to combine a multi-day fasting intervention with comprehensive microbiome characterization and clinically meaningful blood pressure endpoints.

This meta-analysis pooled 7 randomized diet-controlled interventional studies of intermittent fasting in adults with type-2 diabetes (338 total participants, mean BMI 35.7, baseline HbA1c 8.8 percent) to ask the headline question: does IF beat standard caloric-restriction diets for T2D? The answer was nuanced. Intermittent fasting produced significantly more weight loss — about 1.9 kg more than standard diet over comparable durations, with the effect strongest in heavier participants and shorter studies. But the HbA1c effect was a wash: IF was not associated with any further HbA1c reduction beyond what a standard diet achieved (point estimate −0.11 percent, confidence interval crossing zero). Other glycemic markers (fasting glucose, insulin) showed mixed results without clear superiority for either approach. The honest synthesis: at the IF protocols typically studied (mostly 16:8 time-restricted eating, some 5:2 alternate-day patterns), IF helps adherence to a calorie deficit and produces more weight loss, but the metabolic improvement is mediated through weight loss, not through any unique fasting-specific mechanism.

This Cleveland Clinic-affiliated study followed 1,403 patients who were eligible for a protein-sparing modified fast program over 5 years to answer the question the original 1970s PSMF literature could not: does the dramatic short-term weight loss persist? Of those eligible, 879 (63 percent) actually initiated PSMF; the remaining 524 (37 percent) pursued other dietary approaches and served as a comparison cohort. The 1-year outcomes were dramatic and favored PSMF: -7.6 percent body weight in the PSMF arm versus -1.8 percent in the comparison arm, a 5.8-percentage-point difference (p less than 0.01). At 3 years, PSMF still showed an advantage but smaller: -2.3 percent vs -0.9 percent, a 1.4-point difference. By 5 years, the difference had effectively disappeared: -1.4 percent vs -1.0 percent (p=0.64, not statistically significant). The proportion achieving clinically meaningful (≥5 percent) weight loss told the same story: PSMF was strongly favored at 1 and 3 years, equivalent at 5 years. The honest conclusion: PSMF produces substantial short-term weight loss with good durability through year 3, but by year 5 the advantage over conventional dietary care is gone.

The REDUCE-IT trial randomized 8,179 statin-treated adults with elevated triglycerides and either established cardiovascular disease or diabetes plus risk factors to receive 2 grams of icosapent ethyl twice daily (a purified prescription-grade EPA preparation, total daily dose 4 grams) or matching placebo. After a median follow-up of 4.9 years, the icosapent ethyl arm experienced a 25% relative reduction in the primary composite endpoint of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) compared with placebo. Reductions were observed across multiple individual endpoint components, including cardiovascular death. The trial reignited debate over high-dose omega-3 cardiovascular prevention after several earlier mixed-result trials and stands as the largest, longest, and methodologically strongest RCT supporting a cardiovascular benefit from a specific EPA preparation.

This NEJM review summarizes evidence that intermittent fasting regimens — alternate-day fasting, time-restricted eating, and periodic multi-day fasts — engage a "metabolic switch" from glucose-derived energy to fat- and ketone-derived energy after hepatic glycogen is depleted, typically within 12–36 hours of fasting depending on the individual and the protocol. The authors argue that repeated exposure to this switch produces adaptive responses across organ systems, including improved insulin sensitivity, reduced inflammation, increased mitochondrial biogenesis, enhanced autophagy, and improved stress resistance in cells. The review compiles findings from animal models alongside the available human trials at the time of publication. The review notes that, despite preclinical signals being strong and consistent, the human evidence base is more heterogeneous: the largest gains in metabolic markers (fasting insulin, HOMA-IR, lipid profile, inflammatory markers) appear in adults with obesity or metabolic syndrome, while effects in lean, metabolically healthy individuals are smaller. The authors flag practical issues — adherence over months, the early-fast hunger and irritability phase, and the lack of long-term outcome data — as the main barriers to clinical adoption rather than safety in healthy adults.

This 2019 meta-analysis pooled 26 double-blind randomized placebo-controlled trials of omega-3 PUFA supplementation for depression to ask a specific question: does the EPA-to-DHA ratio matter? The authors found that it does, decisively. Formulations that were either pure EPA or majority EPA (60 percent or more EPA) showed clinical benefit for depressive symptoms at relatively low doses (1 gram per day or less), while pure DHA and DHA-majority formulations did not. The therapeutic effect was specific to EPA-dominant supplementation. The mechanism inference is that EPA's anti-inflammatory effects (via resolvins and reduction of pro-inflammatory eicosanoids) drive the antidepressant signal, while DHA's role in neuronal membrane structure does not similarly translate to mood benefit at supplementation doses. The paper is the most-cited recent meta-analysis on omega-3 and depression and has shaped subsequent dosing recommendations: when omega-3 is used adjunctively for depressive disorders, EPA-dominant formulations at sub-gram doses are the evidence-supported choice. The paper does not claim omega-3 replaces antidepressant medication; it supports adjunctive use.

This is the first supervised controlled-feeding trial designed specifically to isolate intermittent fasting's metabolic effects from weight loss. Men with prediabetes were enrolled in a randomized crossover trial: 5 weeks of early time-restricted feeding (eTRF — a 6-hour eating window, with the last meal before 3 p.m.), followed by 5 weeks of a control schedule (12-hour eating window), then crossover. Critically, participants were fed enough food to maintain their weight in both conditions — the eating window changed, but total energy intake did not. Even without weight loss, eTRF improved insulin sensitivity, beta-cell responsiveness, systolic and diastolic blood pressure, oxidative stress (8-isoprostane), and evening appetite. The improvements demonstrate that intermittent fasting's cardiometabolic benefits are not solely mediated by weight loss — circadian alignment of eating and the duration of the daily fasting window have independent effects. The paper has been highly influential because it isolated the eating-window mechanism from the calorie-deficit mechanism.

This is the largest published study of sustained nutritional ketosis as a T2D management strategy. The Virta Health study enrolled 349 adults with type-2 diabetes — 262 in the continuous care intervention (CCI, an app-mediated remote-care program with macronutrient guidance toward sustained nutritional ketosis) and 87 in usual care. The design was open-label and non-randomized (participants self-selected into the intervention), so it sits below DiRECT's RCT evidence in the hierarchy — but the sample is larger and the duration is longer. At one year, the intervention group's HbA1c fell from 7.6 to 6.3 percent (the threshold for diabetes remission), mean weight loss was 13.8 kg, and 94 percent of insulin users reduced or eliminated insulin therapy. Sulfonylureas were discontinued completely in the CCI group. Secondary markers improved across the board: HOMA-IR dropped 55 percent, hsCRP dropped 39 percent, triglycerides dropped 24 percent, HDL-C rose 18 percent. The usual-care arm showed no meaningful change on any of these endpoints.

This review formalized the term "metabolic switch" — the transition from carbohydrate-derived energy to fatty-acid- and ketone-derived energy that occurs after liver glycogen stores are depleted, typically beyond about twelve hours of fasting depending on prior carbohydrate intake and activity. The authors synthesize the mechanistic literature on intermittent fasting protocols (alternate-day fasting, time-restricted feeding, periodic multi-day fasts) and argue that repeated engagement of this metabolic switch is what produces the adaptations associated with intermittent fasting: improvements in insulin sensitivity, lipid profile, blood pressure, inflammatory markers, and stress resistance. The review is positioned as a translational document for clinicians beginning to recommend intermittent fasting and emphasizes that the *frequency* of switching, not just the *duration* of any single fast, is plausibly the parameter that drives adaptation.

This Nature Reviews Neuroscience paper from Mark Mattson — the most cited researcher on fasting and brain health — synthesizes the case that periodic shifts between fed and fasted metabolic states are essential for optimal brain function. Mattson coined the term "intermittent metabolic switching" (IMS) for the pattern: eating depletes liver glycogen, fasting forces ketone production, and the cycle repeats. The review argues this oscillation is what humans evolved with, and that modern continuous-feeding patterns disrupt it with cognitive and neurological consequences. The mechanistic story focuses on β-hydroxybutyrate (BHB), which is transported into neuronal mitochondria as fuel but also acts as a signaling molecule. BHB induces brain-derived neurotrophic factor (BDNF), which promotes synaptic plasticity, neurogenesis in the hippocampus, and resistance to neuronal injury. Mattson reviews evidence connecting IMS to improved cognition, mood regulation, motor performance, autonomic-nervous-system function, and resistance to neurodegenerative disease. The framework has shaped subsequent fasting-and-brain-health research and is heavily cited in popular literature on fasting's cognitive benefits.

Open-access narrative review by DiNicolantonio and O'Keefe arguing that the marked increase in dietary linoleic acid (LA, the dominant omega-6 fatty acid in industrial seed oils) is a primary driver of coronary heart disease via the production of oxidized LDL particles enriched in oxidized linoleic acid metabolites (OXLAMs). The paper synthesizes evidence that LA intake has risen from roughly 1–2% of energy in the early 20th century to 8–10% today, that LA accumulates in adipose tissue with a half-life on the order of two years, and that oxidized LA species are inflammatory and atherogenic. The mechanism proposed: industrial vegetable oil consumption raises tissue LA, raises OXLAM production, and contributes to atheroma formation independent of cholesterol per se.

DiRECT is the trial that proved type-2 diabetes is reversible through structured weight loss in routine primary care. 306 adults aged 20–65 with T2D diagnosed within the past six years and BMI 27–45 were enrolled across 49 GP practices in Scotland and Tyneside; the practices, not the patients, were randomised. The intervention had three phases: total diet replacement (an 825–853 kcal/day formula diet for 3–5 months) with diabetes and blood-pressure medications stopped, structured food reintroduction over 2–8 weeks, then long-term weight-maintenance support. At 12 months, 46% of intervention participants achieved diabetes remission (HbA1c < 6.5% off all glucose-lowering medications) compared to 4% of usual-care controls. Mean weight loss was 10 kg in the intervention arm versus 1 kg in the control arm. Remission tracked weight loss tightly: 86% of those losing ≥15 kg achieved remission, while none who gained weight did.

This is the most-cited review of whether fasting and calorie restriction actually trigger autophagy — the cellular self-cleaning process that recycles damaged proteins and organelles. The authors surveyed studies across cell culture, rodent models, and human subjects, looking at autophagy markers such as LC3 lipidation, p62 turnover, ATG7 expression, and mTOR signalling under various fasting and calorie-restriction protocols. Their headline conclusion is that fasting and calorie restriction reliably upregulate autophagy across a wide variety of tissues and organs — liver, muscle, brain, heart, kidney — and that the effect is robust. They also note that autophagy is mechanistically central to the longevity and disease-prevention benefits of caloric restriction: blocking autophagy in animal models attenuates those benefits. The evidence base, however, leans heavily on rodent and cell-culture work; direct measurement of autophagy in living humans is limited because most autophagy markers require tissue biopsy.